+351 211 369 829 
Our platform(s)
New in vitro diagnostics medical devices are essential in oncology to improve early detection, diagnosis, and treatment of cancer, ultimately leading to better patient outcomes. Finding biomarkers that are clinically relevant and effective in a real-world setting is a challenging process that requires rigorous testing and validation. At Ophiomics we developed a unique approach to biomarker discovery centred around addressing strong clinical questions and minimising technical, clinical, and commercial uncertainties, enabling us to maximize the chances of bringing impactful products to market and positively impacting patients’ lives. We conceptualise our approach in three stages, as illustrated below.
Novel solutions for unmet clinical needs
At Ophiomics Discoveries, we validate and refine clinical questions raised by clinicians and patients, while carefully assessing their economic viability. We discover feasible biomarkers by harnessing data-mining to analyse large volumes of omics data, including fragmented nuclei acids from liquid biopsies or FFPE tissues. Our output is a decision algorithm with well-defined predictive variables paired with a laboratory assay design, and respective proof of concept results.
-
Physicians and Scientists
Concerned about unmet clinical needs that would benefit from a biomarker-based decision.
-
Companies and Clinical Teams
Requiring large-scale data analysis to identify biomarkers able to stratify groups of patients, for example within clinical trials.
Transforming discoveries into market-ready IVD products
At Ophiomics Develop, we use a standardised process to transform proof of concept-level essays into fully industrialised and market-ready products. Product prototypes are developed in our ISO 13485 – certified pilot manufacturing facility, supported by our R&D laboratory in clinical validation studies. We combine the technical platforms for FFPE and liquid biopsies with a deep understanding of the regulatory framework of IVD medical devices and decision algorithms.
-
Physicians and Scientists
Who wish to licence a discovery and collaborate with an industrial partner to develop a clinical product that can directly impact patients’ lives.
-
Companies and Clinical Teams
That already identified clinically relevant biomarkers for patient stratification and wish support in developing a companion diagnostic.
-
Tech Transfer offices
Who wish to engage an industrial partner to evaluate and licence biomarker/diagnostic algorithm discoveries from an Institutional portfolio.
Bringing meaningful products to market
At Ophiomics go-to-market, we conduct market studies and devise strategies for early clinical prototyping of our products. We include clinical studies and limited clinical use of the products from an early stage of the process, as we firmly believe that early commercial validation is critical for the success of our products.
-
Biotech/MedTech Companies
With products that can be synergistic with our portfolio and that wish to discuss possibilities of technical and/or commercial collaboration.
-
Distributors and Commercial Partners
With demonstrated access to relevant markets, that wish to partner with Ophiomics to commercialise one or more of our products.
Ophiomics Pipeline
 |
|||||||
|---|---|---|---|---|---|---|---|
| Clinical need | Product | Sample | Discover | Develop | Validate | Commercialise | Milestones |
| Liver cancer patient stratification for transplantation |  |
FFPE | Q3 2023:
3+ validation cohorts completed |
||||
| Diagnosis and prognosis of Barrett's Esophagus |  |
FFPE | Q4 2023: 2+ validation cohorts completed |
||||
| Liquid biopsy for ealy liver cancer detection in cirrhotic patients |  |
Blood | Q1 2024 1+ validation cohort completed |
||||